These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 22147937)
61. Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future. Soo RA; Adjei AA J Thorac Oncol; 2017 Apr; 12(4):602-606. PubMed ID: 28343541 [No Abstract] [Full Text] [Related]
62. TRACERx: Tracking tumor evolution to impact the course of lung cancer. Negrao MV; Quek K; Zhang J; Sepesi B J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1199-1202. PubMed ID: 29331175 [No Abstract] [Full Text] [Related]
63. Biomarker-Driven Staging-Are We There Yet? Devarakonda S; Govindan R JAMA Netw Open; 2019 Dec; 2(12):e1917052. PubMed ID: 31808918 [No Abstract] [Full Text] [Related]
64. Commentary: How to "spot" a leopard: It's in the genes. Lazar JF J Thorac Cardiovasc Surg; 2020 Aug; 160(2):e82-e83. PubMed ID: 32113723 [No Abstract] [Full Text] [Related]
65. Letter to Editor: A simple and cheap workflow to standardize cell block method in non small cell lung cancer patients. Parente P; Biancofiore G; Graziano P Virchows Arch; 2022 Oct; 481(4):677-678. PubMed ID: 35997824 [No Abstract] [Full Text] [Related]
66. Response to Letter to the Editor. Jett JR; Kim ES J Thorac Oncol; 2020 Jul; 15(7):e110-e111. PubMed ID: 32536542 [No Abstract] [Full Text] [Related]
67. A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment. Ng SS; Leonardelli S; Hölzel M Signal Transduct Target Ther; 2021 Nov; 6(1):394. PubMed ID: 34764260 [No Abstract] [Full Text] [Related]
68. Reply to the letter to the editor 'What is the clinical impact of the LUX-Lung 5 trial?' by Addeo. Schuler M; Yang JC; Planchard D Ann Oncol; 2016 Jun; 27(6):1172-1173. PubMed ID: 27029703 [No Abstract] [Full Text] [Related]
69. Letter to the Editor. Tamura T; Satoh H Clin Lung Cancer; 2016 Sep; 17(5):e185. PubMed ID: 27236383 [No Abstract] [Full Text] [Related]
70. Letter in response to: Identifying risk in the use of tumor markers to improve patient safety. Dayyani F; Morgenstern D Clin Chem Lab Med; 2016 Dec; 54(12):e383-e384. PubMed ID: 27467754 [No Abstract] [Full Text] [Related]
71. Dynamic change of IDO1 activity predicts survival in patients with unresectable stage III NSCLC and chemoradiotherapy. Wu L; Wang D; Chen Y; Qian M; Xu X; Zhang T; Bi N; Wang L Front Immunol; 2022; 13():906815. PubMed ID: 36032151 [TBL] [Abstract][Full Text] [Related]
72. Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy. Zhu Y; Jiang C; Liu Y; Li Y; Wu H; Feng J; Xu Y Ann Transl Med; 2020 Sep; 8(18):1169. PubMed ID: 33241018 [TBL] [Abstract][Full Text] [Related]
73. A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma. Zou X; Hu Z; Huang C; Chang J Med Sci Monit; 2020 Jul; 26():e924269. PubMed ID: 32613949 [TBL] [Abstract][Full Text] [Related]
74. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Usó M; Jantus-Lewintre E; Bremnes RM; Calabuig S; Blasco A; Pastor E; Borreda I; Molina-Pinelo S; Paz-Ares L; Guijarro R; Martorell M; Forteza J; Camps C; Sirera R Oncotarget; 2016 Aug; 7(33):52849-52861. PubMed ID: 27463005 [TBL] [Abstract][Full Text] [Related]
76. Validation of a reverse transcription-polymerase chain reaction-based five-gene signature in non-small cell lung cancer. Ruco L; Scarpino S; Natoli G J Thorac Oncol; 2009 May; 4(5):670. PubMed ID: 19395916 [No Abstract] [Full Text] [Related]
77. Clinical implication of microrna for lung cancer. Wang Y; Zhang X; Liu L; Li H; Yu J; Wang C; Ren X Cancer Biother Radiopharm; 2013 May; 28(4):261-7. PubMed ID: 23496233 [TBL] [Abstract][Full Text] [Related]